Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Ettrich

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2026
Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629)Ralf-Dieter Hofheinz, Ludwig Fischer von Weikersthal, Tobias Dechow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)Dominik P Modest, Uwe M Martens, Jorge Riera-Knorrenschild, et al.
Frontiers in Oncology|November 1, 2023
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, et al.
British Journal of Cancer|October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
United European Gastroenterology Journal|March 28, 2020
Pancreatic cancer-derived organoids - a disease modeling tool to predict drug responsePierre-Olivier Frappart, Karolin Walter, Johann Gout, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf-Dieter Hofheinz, Kirsten Merx, Georg M Haag, et al.
JAMA Oncology|June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical TrialAlexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2026
Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629)Ralf-Dieter Hofheinz, Ludwig Fischer von Weikersthal, Tobias Dechow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)Dominik P Modest, Uwe M Martens, Jorge Riera-Knorrenschild, et al.
Frontiers in Oncology|November 1, 2023
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, et al.
British Journal of Cancer|October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
United European Gastroenterology Journal|March 28, 2020
Pancreatic cancer-derived organoids - a disease modeling tool to predict drug responsePierre-Olivier Frappart, Karolin Walter, Johann Gout, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf-Dieter Hofheinz, Kirsten Merx, Georg M Haag, et al.
JAMA Oncology|June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical TrialAlexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Pageof 2